????? Nephrotic Syndrome - PowerPoint PPT Presentation

1 / 80
About This Presentation
Title:

????? Nephrotic Syndrome

Description:

Title: PowerPoint Presentation Created Date: 1/1/1601 12:00:00 AM Document presentation format: Other titles: Times New Roman Garamond ... – PowerPoint PPT presentation

Number of Views:380
Avg rating:3.0/5.0
Slides: 81
Provided by: gxsbE21C
Category:

less

Transcript and Presenter's Notes

Title: ????? Nephrotic Syndrome


1
?????Nephrotic Syndrome
  • ?????????? ???

2
Definition
  • Nephrotic syndrome (NS) is defined by the
    presence of following
  • Heavy proteinuria (gt3.5g/d)
  • Hypoalbuminemia (serum albumin lt30g/L)
  • Peripheral edema
  • Hyperlipidemia / hypercholesterolemia

3
Major causes of NS (primary or idiopathic)
  • Minimal change disease (?????)
  • Mesangial proliferative glomerulonephritis
    (??????????)
  • Focal segmental glomerulonephritis (????????????)
  • Membranous glomerulonephritis (????)
  • Membranoproliferative glomerulonephritis
    (?????????/????????????)

4
Major causes of NS (secondary or systemic)
  • Antoimmune systemic lupus erythematosus (SLE)
  • Endocrine diabetic nephropathy
  • Infections Hepatitis B, C, HIV
  • Allergenic Henoch-Schonlen purpura
  • Neoplastic Hodgkins and non-Hodgkins
    lymphomas, multiple myeloma
  • Others Amyloidosis, Hereditary nephritis,
    medications

5
Pathophysiology
  • Heavy protinuria
  • Hypoalbuminemia
  • Edema
  • Hyperlipidemia

6
Heavy proteinuria
  • Damage to the charge-selective barrier of GMB
    ?ultrafiltration of negatively charged albumin
  • Damage to the size-selective barrier of GMB
    ?passsage of lager molecular proteins
  • Protein filtration gt reabsorption capacity of
    tubules
  • Heperperfusion/Hyperfiltration factors
    (hypertension, protein-rich diet) ?proteinuria
    increase

7
Consequence of urinary loss of plasma proteins
  • Serum protein ?or hypoalbuminemia
  • IgG/Complement ??infection
  • Coagulation component alternation (anticoagulants
    ?)?thrombosis
  • Hormone-binding proteins ?/metal-binding proteins
    ??endocrine or metabolic abnormalities
  • Lager proteins may increase

8
Hypoalbuminemia
  • Urinary loss
  • albumin catabolism ? by tubules
  • Malnutrition due to GI changes

9
Edema
  • Reduced plasma oncotic pressure (colloid osmotic
    pressure)
  • Hypovolemia ?renin-angiotensin-aldosteron ?
    Sympathetic nervouse and vasopression systems ?
  • Primary renal Na retension (non-plasma Hormone
    effects on the kidney)

10
Hyperlipidemia
  • One of the sentinel features of NS with numerous
    alterations in lipids profiles (hypercholesterolem
    ia, hypertriglyceridemia, LDL and VLDL ?)
  • Overproduction by the liver of lipoproteins
  • Decreased catabolism of lipoproteins and
    triglyceride

11
Minimal changes nephropathy(MCD, ???????)
  • Overview and Terminology
  • First described in 1913 by Monk as lipoid
    nephrosis
  • other terms nil disease and idiopathic
    nephrotic syndrome

12
Pathogenesis
  • Unclear
  • Most likely a consequence of T cell abnormalities
    (glomerular permembility factor)
  • Other potential mechanisms (circulating immune
    complexes)

13
Histopathology
  • Light microscope (LM)
  • Lack alteration in glomerular structure
  • Some lipid droplets in tubule cells
  • Immunoflurescent microscopy( IM)
  • No change
  • Electron microscopy (EM)
  • Fusion of epithelial foot processes

14
(No Transcript)
15
(No Transcript)
16
Clinical presentation
  • Most common in children accouting for 10-15 of
    NS in adults with male predominance
  • Typical feature of NS
  • Uncommon with nephritic features (hematuria,
    hypertension)
  • Renal function (normal or dereasesd transiterily)

17
Diagonosis
  • Children and prealdolescent children presenting
    with NS will have MCD (about 80-85)
  • Children with NS sensitive to steroid treatment
  • Secondary MCD kept in mind when adult or old
    patients presents with MCD
  • Renal biopsy

18
Treatment (1)
  • Corticosteroid therapy
  • Exquisitely sensitive
  • Dose of prednisone
  • Caution with the side-effects of steroid

19
Dose of prednisone
  • Initial
  • (full)
  • Tapering(slowly)
  • Maintainece
  • (longer)
  • Adult
  • 1 mg/kg/d8-12w
  • 10reduction/1-2w
  • Effetively minimal dose(10mg/d)6-12m
  • Children
  • 2mg/kg/dlt60mg/d8-12w
  • 10reduction/1-2w
  • Effetively minimal dose(10mg/d)6-12m

20
Treatment (2)
  • Cytotoxic therapy
  • For patients with more relapses,
    steroid-dependant or steroid-resistant
  • Cyclophosphamide
  • 2mg.kg-1.d-1 total dose 6-8g side-effects
  • Chlorambucil (?????)
  • 0.1-0.2mg/kg/d for 8 weeks

21
Treatment(3)
  • Cyclosporine
  • Selectively inhibits Th, Tc
  • As the second line medication to treat patients
    with steroid-resistant, frequently
    relapsing/steroid-dependent MCD
  • 5 mg .kg-1.d-1 for 8-12 weeks, then tapering
  • Side effects

22
Treatment (4)
  • Other medications MMF
  • General therapy
  • Symptomatic treatment
  • Chinese medicine

23
Mesangial proliferative glomerulonephritis(MsPGN,
??????????)
24
Overview and Terminology
  • MsPGN is a morphlogic entity and characterized by
    glomerular mesangial hypercellularity
  • This morphologic definition includes many
    well-characterized GNs (IgA nephropathy,
    Henoch-Schonlein purpura nephritis, lupus
    nephritis and others)
  • When these well-defined entities are diagnosed
    and excluded, the resuliting are known as MsPGN
    or non-IgA MsPGN

25
Pathogenesis
  • Unclear
  • Possibly due to immune complex depositon and
    complement fixation
  • Altered mesangial function may play an active role

26
Clinic presentation
  • More in adolescents and young adults, more male
    patients
  • 50 of patients with a pre-episode of upper
    respiratory tract infection
  • 70 of patients with hematuria
  • Some patients with mild hypertension, azotemia
  • Accounting for 20-25 of renal biopsed patients
    and 30 of primary NS

27
Histopathology
  • LM
  • Varying degrees of mesangial hypercellularity
    with an increase in mesangial matrix
  • IM
  • IgG, IgM, C3 deposition in mesangial region
    and/or in capillary wall in granular pattern
  • EM
  • Elctron-dense deposits in the mesangium

28
(No Transcript)
29
(No Transcript)
30
Differential diagnosis
  • Clinical presentation
  • Renal biopsy
  • Exclusion of the secondary GN and other primary
    glomerulopathies (IgA nephropathy)

31
Treatment
  • Therapy for MsPGN not-defined
  • Efficacy of steroid or cytotoxic therapy depends
    on the degree of pathologic injury
  • Other medications (ACEI /ARB /Chinese medicine)

32
Membranous Nephropathy(MN, ????)
  • Overview and Terminology
  • Most common pattern of idiopathic NS in adults,
    less common than MCD in children
  • 15-25 of MN adult patients with no associated
    systemic illnesses
  • Up to 30 of MN patients with associated systemic
    illnesses(SLE,HBV,tumors)

33
Pathogenesis
  • Immune complex formation in situ at the
    subepithelial capillary wall
  • Deposition of circulating immune complexes
  • Complement activation ?proteinuria

34
Clinical presentation
  • Heavy proteinuria in more than 80 of patients
    with full expression of NS
  • 30 of patients with microscopic hematuria
  • More male patients and more severe
  • 80-90 of patients old than 30 years at
    diagnosis
  • The older the patients, the greater possibility
    of malignancy
  • Most common pattern of NS associated with venous
    thromboses

35
Histopathology
  • Usually classified as four stages
  • LM capillary walls thickened with
    subepithelial projections (Spikes)
  • IM strong granular capillary wall
    staining for IgG, C3
  • EM subepithelial electron-dense
    deposits all along the capillary walls

36
(No Transcript)
37
(No Transcript)
38
(No Transcript)
39
Diagnosis(1)
  • Based on histological findings in patients whose
    history, physical examination and appropriated
    laboratory tests exclue the likelihood of a
    secondary cause

40
Diagnosis(2)
  • Following lab tests negtive or normal
  • Antinuclear Ab
  • Anti-DNA Ab
  • Rheumatoid factor
  • Glycosylated HB
  • Hepatitis Ag or Ab
  • Carcinoembryonic Ag
  • cryoglobulins

41
Treatment (1)
  • Treatment of idiopathic MN remains
    controversial and should be individualized
  • SteroidsCytotoxic (ponticelli protocol)

42
Ponticelli protocol
  • Months 1, 3, 5 methylprednisone 1.0 iv qd3d
  • Months 2, 4, 6 chlorambucil 0.2mg/kg/d
  • then methylprednisone 0.4mg/kg/d27d

43
Treatment (2)
  • Immune inhibition agents(MMF,??)
  • ACEI/ARB
  • Other therapies (anticoagulation)

44
Focal segmental glomerulosclerosis(FSGS,
??????????)
45
Terminology
  • Focal vs diffuse
  • Some glomeruli involved (focal)
  • All glomoruli involved (diffuse)
  • Segmental vs global (dealing with individual
    glomerulus)
  • Only part of the glomerulus involved (segmental)
  • Whole golmerulus involved (global)

46
Overview
  • Accounting for less than 15 of cases of
    idiopathic NS in children, but more in adults
  • Hematuria,hypertension and GFR?often found in
    patients at presentation

47
Pathogenesis
  • Loss of renal mass( compensatory theory)
  • GEC injury
  • RAS activation
  • Cytokine overproduction(TGF-ß)

48
Clinical presentaion
  • Most patients with idiopathic FSGS present with
    asymptomatic proteinuria or full NS
  • Detection of asympotomatic cases occurs often at
    physicals
  • Patients with NS present with edema

49
Histopathology
  • LM focal segmental distribution of sclerosis
    (mesangial matrix ?,capillary lumen obliteration,
    adhesion to Bowmans capsule)
  • IM IgM and C3 deposition in focal areas(?????)
  • EM some or extensive effacement of foot process

50
(No Transcript)
51
Diagnosis
  • Renal biopsy required
  • Few glomerular sampling may not find the
    sclerotic glomerulus
  • Finding of tubular fibrosis in such biopsy may
    suggest the possibility of unobserved sclerosis
    glomeruli
  • Patients thought to have MCD with a poor response
    to steroids or cytotoxic may have FSGS

52
Treatment
  • FSGS with normal renal function
  • More intensive and more prolonged
    immunosuppressive therapy(6-12months, steroid,
    cytotoxic, cyclosporine, MMF)
  • ACEI/ARB
  • FSGS with GFR decrease
  • Follow the therapies for chronic renal failure

53
Membranoproliferative glomerulonephritis(MPGN,???
??????)
54
Overview and Terminology
  • Other terms as mesangiocapillary
    GN(????????????)Lobular GN(????????)Hypocmplem
    entemic GN(??????)
  • Secondary conditions are more common than the
    idiopathic forms

55
Pathogenesis
  • Immune complex deposition in the mesangial and
    capillary wall ?C activation(for MPGN type ?)
  • MPGN type ?does not appear to involve immune
    complex, but rather utilize some other mechanism
    for C activation

56
Clinical presentation
  • Less common entity of NS, but if it occurs, most
    in children and young adults
  • Patients present with Nephrotic (type ?, 2/3 slow
    progression), Nephritic(type ?, 5, aggressive)
    or in combination features
  • Preceding upper respiratory infection and
    persistent proteinuria, hematuria,
    hypocomplementemic, anemia indicate an incidence
    of MPGN

57
Histopathology
  • LM marked mesangial proliferation and
    thickening of GBM, glomrular lobularity, double
    contours(tram-tracks)
  • IM IgG and C3 granular deposits in mesangium
    and capillary walls
  • EM subendothelial and mesangial electron-dense
    deposits

58
(No Transcript)
59
(No Transcript)
60
Diagnosis
  • Clinical features
  • Persistent hypocomplementemia, anemia not
    compatible with renal damage, nephrotic with
    hemoturia, early hypertension and GFR?
  • Renal biopsy with exclusion of secondary MPGN

61
Treatment and prognosis
  • Effective therapy needed
  • Steroid and cytotoxic maybe effective on some
    younger age patients
  • Symptomatic therapies( anticoagulation)
  • Renal function protecting therapies
  • Poor prognosis, 50of patients following 10 year
    course progress to ESRD

62
? ?
  • ?????????
  • ???gt3.5g/d
  • ???????30g/L
  • ??
  • ????
  • 1,2???NS???

63
?????????
  • ???
  • ???????(MCD)
  • ??????????(MsPGN)
  • ????(MN)
  • ??????????(FSGS)
  • ?????????(MPGN)

64
  • ???
  • ????????
  • ??????????
  • ?????
  • ???????
  • ??????
  • ??????

65
????
  • ????????????????
  • ?????????????????????
  • ????????????????RAS???????????
  • ?????????,?????????

66
???????
  • ????????,?????,????
  • ????LM??,IM(-),EM???????
  • ?????90??????????,??????60

67
??????????
  • ????????,??????50,??????,?????,????
  • ????LM ???????,IM???IgG,IgM,C3?????,EM???????
    ?
  • ????????????????????????

68
????
  • ???????????,????,????????,???????
  • ????LM ???????,GBM?? IM IgG,C3?????? EM
    GBM????????,????
  • ????????????????????? (ponticelli??)
    ??????,?20-35???????????

69
??????????
  • ???????????????????????GFR?
  • ????LM ??????IM IgM,C3??????,EM
    ?????????
  • ?????????????????,???????

70
?????????
  • ??????????,????,???,??????????,?????
  • ????LM ?????????,??????,???IM
    IgG,C3??????????????EM ?????????????
  • ?????????,????,?????,?????,???

71
???????
  • ????????,??????,????
  • ??????????????????????????
  • ?????????????????????????????
  • ??????????

72
??
  • ??NS
  • ???????????????
  • ???????

73
????
  • ?????????
  • ?????????,????,??????,?????????
  • ?????????,?????,????()
  • DN????,????

74
  • ????????????,??????(???????),???
  • ????????????,??,?????????,?????M?,????????
  • ???????

75
? ?
  • ??????
  • ????
  • ????
  • ??????
  • ????
  • ????
  • ?????????????????

76
??
  • ?????
  • ?????
  • CTX
  • MMF
  • CsA?FK506
  • ????(???)
  • ?????

77
Questions
  • This 5-year-old boy has 4 protein in his urine
    on stick testing. His serum albumin is 21g/L.
    What is the most likely diagnosis?

78
  • These picture are from the renal biopsy of a
    60-year-old man who presented with nephrotic
    syndrome. What is the diagnosis?

79
  • How to treat minimal change disease patients with
    steroid?

80
Thank You!
Write a Comment
User Comments (0)
About PowerShow.com